Use of adjunctive stimulants in adult bipolar depression.
Bipolar depression represents a high priority research field, due to its pervasiveness, and high economic and personal (suicidality, impaired function, quality of life) costs, and the limited evidence base to inform therapeutics. Mood stabilizers and second-generation antipsychotics for bipolar depression are commonly only partially effective, and their side-effects may overlap with depressive symptoms such as hypersomnia, daytime drowsiness, fatigue, psychomotor retardation, and weight gain. Moreover, the use of antidepressants in bipolar depression is controversial due to concerns regarding the risks of inefficacy or switching to mood elevation. Stimulants and related compounds such as modafinil and armodafinil have on occasion been used as adjuncts in bipolar depressed patients with encouraging results, but their use is limited by the paucity of systematic evidence of efficacy and safety. The present review aims to provide an updated perspective on the use of stimulants and stimulant-like medications in adult bipolar depression, considering not only recent randomized controlled trials, but also open naturalistic studies, in order to clarify the strengths and limitations of using these agents.
Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico, Milan, Italy. bernardo.dellosso@unimi.it
Bernardo
B
Dell'Osso
Terence A
TA
Ketter
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001559:Benzhydryl Compounds / Q000008:administration & dosage; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage; D000077408:Modafinil
D014150:Antipsychotic Agents; D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D000077408:Modafinil